After Incyte’s (INCY) abstract of preliminary data from INCB0989 in myelofibrosis was posted on the ASH 2025 website, Mizuho believes the efficacy data look “promising” and safety “looks fine,” adding that its “still early.” The firm has a Neutral rating and $90 price target on Incyte shares, which are up $5.42, or 6% to $98.90 in Monday afternoon trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s INCA033989 Shows Promising Initial Results in Myelofibrosis, But Hold Rating Reflects Need for Further Data
- Wells Fargo believes Incyte shares should trade up on INCB0989 abstract
- Incyte upgraded to Buy from Neutral at Guggenheim
- Knight Therapeutics announces approval, launch of MINJUVI in Argentina
- Incyte price target raised to $93 from $79 at Truist